Oral progesterone 100, 200, or 300 mg daily was given for the first 10 days of each calendar month to postmenopausal women also receiving conjugated oestrogens 125 mg daily continuously. Endometrial biopsy specimens were taken on the sixth day of the third or subsequent cycle of combined treatment for histological, ultrastructural, and biochemical evaluation.
Introduction
Within the endometrium endogenous or exogenous oestrogens stimulate cell mitosis and proliferation and increase DNA synthesis and the concentration of nuclear oestradiol receptor. Endogenous progesterone in the secretory phase of the ovulatory cycle causes morphological changes within the endometrium. Secretory and ultrastructural features develop and the latter include nucleolar channel systems, giant mitochondria, and subnuclear accumulations of glycogen.1 2 Biochemically, progesterone exposure exerts an antimitotic or antioestrogenic effect in reducing DNA synthesis and nuclear oestradiol receptor3 and exerts a secretory effect by increasing the activities of certain enzymes such as oestradiol-17 and isocitric dehydrogenases.4
Endogenous progesterone production in normal postmenopausal women is invariably insufficient to produce an endometrial response. But when used in combination with exogenous oestrogens, synthetic progestogens reproduce the characteristic morphological and biochemical changes of the secretory phase of the ovulatory cycle.5 6 These changes have important clinical implications because thev are currently believed to be part of the mechanism whereby the addition of a progestogen to postmenopausal oestrogen treatment reduces the incidence of endometrial hyperplasia and possibly carcinoma, as compared with the incidence with oestrogen treatment alone.7 Unfortunately, the administration of certain progestogens may not be without risk. The increased incidence of hypertension and arterial thromboembolic disease in women taking oral contraceptives has been linked to the progestogen component in a dose dependent manner.0-12 In the United States the National Institutes of Health appear to have extrapolated these data to the postmenopausal situation and have cautioned against the widespread addition of progestogens to exogenous oestrogen treatment. '3 Two progestogens widely used with postmenopausal oestrogen treatment, norethisterone and DL-norgestrel, are both derivatives of 19-nortestosterone and as such possess androgenic activity. They increase plasma insulin concentrations,'4 15 which reflects decreased insulin sensitivity and therefore impaired glucose tolerance, and they both lower the concentration of cholesterol in the high density lipoprotein fraction of plasma.'6 1' This is a potentially serious side effect because the incidence of cardio-vascular disease in both men and women is inversely related to the high density lipoprotein cholesterol concentration. '8 19 Hence the beneficial effects of long term postmenopausal oestrogen treatment in possibly reducing mortality from ischaemic heart disease20 may be negated by their addition. A progestogen without these metabolic effects is therefore desirable.
Progesterone does not adversely affect plasma high density lipoprotein cholesterol concentrations2' and causes only minimal changes in carbohydrate metabolism. 22 Although we have reported that 25O' of an oral dose of progesterone appears in the peripheral circulation and that plasma concentrations within the luteal phase range are maintained for up to seven hours after ingestion,23 the belief that oral progesterone is inactive and without end organ effect has recently been restated. 24 We have determined the morphological and biochemical changes within the oestrogen primed postmenopausal endometrium after varying doses of micronised progesterone taken by mouth. For comparative purposes endometrial biopsy specimens were obtained from postmenopausal women during the oestrogen only phase of treatment, and from premenopausal women with the assumption that proliferative phase samples would give an index of physiological oestrogen activity and that secretory phase samples during days 17 to 21 would provide the range of normal progesterone function. The endometrial specimens were assessed histologically after staining with haematoxylin and eosin. Fragmented detached epithelium and glands were considered unreliable for assessment and special care was taken to exclude basal layer, isthmic, and endocervical tissue. Features assessed were those of the normal menstrual cycle.
Patients and methods
In the absence of any secretory features, small glands with some nuclear stratification were classified as proliferative when mitotic figures were seen or as non-secretory when mitoses were absent. In very small sections it was sometimes difficult to distinguish nonsecretory glands from a poorly developed late secretory pattern: doubtful cases were classified as non-secretory.
Endometrial hyperplasia and atypia were assessed by the presence of (a) abnormalities of tissue architecture including an increased ratio of glands to stroma and cystic or adenomatous features and (b) cell hyperplasia including increased stratification, tufting, and nuclear atypia. Assessments were sometimes difficult in small specimens, however, and minimal changes confined to one small area of the specimen were not diagnosed as hyperplasia.
The morphological changes within the endometrium were assessed using a simple scoring system. Subnuclear glycogen is deposited just before and giant mitochondria develop immediately after ovulation in the normal ovulatory cycle. Nucleolar channel systems become visible three days after ovulation and remain for three or four days.' 2 BRITISH MEDICAL JOURNAL VOLUME 287 29 OCTOBER 1983 The presence of each of these features in the postmenopausal endometrial samples was accorded a score of one point, and no score was given when they were absent. Early secretory changes observed by light microscopy also scored one point if present. DNA synthesis was measured as described 28; and is expressed for epithelium as the number of cells labelled per 100-that is, the labelling index; stromal DNA synthesis is expressed as the number of labelled cells per high power field (magnification x' 100). Nuclear oestradiol receptor and the activities of oestradiol-17,Q and isocitric dehydrogenases were also measured as described.2" 28
The lower limits of sensitivities of the biochemical assays were as follows: epithelial labelling index 02 ', stromal DNA synthesis 0-2 labelled cells; nuclear oestradiol receptor 0 2 pmol (54 5 pg) mg DNA; oestradiol-17)3 dehydrogenase 9 nmol (2) (3) (4) [Lg) of oestrone formed per mg DNA an hour; and isocitric dehydrogenase 100 nmol (74-5 jog) of reduced nicotinamide adenine dinucleotide phosphate formed per mg DNA a minute. Statistical analyses of the biochemical data were by Student's t test.
The morphological and biochemical investigations were performed without knowledge of the treatment regimen.
Results
The comparative premenopausal and postmenopausal oestrogen only data referred to above are included where appropriate. LIGHT 
MICROSCOPY
Eleven of the 15 patients taking 100 mg progesterone provided endometrium sufficient for accurate assessment. Three samples (27,,) showed mild to moderate atypical hyperplasia, and one of these also contained secretory changes. One patient had proliferative endometrium, while a non-secretory pattern was diagnosed in three samples (27",,) . In four patients (36",,) varying degrees of secretory change were seen, ranging from early to late patterns. -001) (fig 1) . With progesterone 200 mg and Ultrastructural and secretory features in endometrium of postmenopausal women treated with conjugated equine oestrogens 1-25 mg continuously either alone or with progesterone 100 mg, 200 mag, or 300 mg daily added for 10 days each month. Proliferative and secretory phase data for days 1 7-21 (5) (12) (1 (1) zU - 300 mg the values were not significantly different from the secretory phase range but they were significantly higher with 100 mg (p < 0-05). Stromal DNA synthesis was not significantly reduced by the 100 mg dose but was lowered by 200 mg (p < 0 01) and 300 mg (p < 0 001). With no dose of progesterone was there a significant difference from the values observed in the secretory phase samples. Significant differences in suppression of both epithelial and stromal DNA synthesis were observed between the 300 mg and 100 mg progesterone doses (p < 0-05 for both).
Nuclear oestradiol receptor concentrations seen in conjugated oestrogen treated endometria were reduced by all progesterone doses (fig 2) , and with the two higher doses this was highly significant (p <0-001). With progesterone 300 mg this reduction was to below the secretory phase range (p < 0 05), while with 100 mg the values were significantly higher than those of the secretory phase (p < 0 05). The 300 mg dose achieved significantly greater depression of nuclear oestradiol receptor value than did the 100 mg dose (p < 0 02).
As compared with oestrogen only treatment, the activity of oestradiol-17( dehydrogenase was significantly increased during treatment with all three progesterone doses (p < 0 001) (fig 3) . With progesterone 100 mg, however, the values were significantly lower than the secretory phase range (p < 0-001). Induction of oestradiol-17 p dehydrogenase activity was significantly greater with 300 mg as compared with 200 mg (p < 0-01), and with 200 mg as compared with 100 mg (p < 002).
Isocitric dehydrogenase activity was not increased by the 100 mg dose and was significantly lower than the secretory phase range (p < 0 001). Progesterone 200 mg and 300 mg significantly increased isocitric dehydrogenase activity as compared with conjugated oestrogen treatment (p <001 and p <0001, respectively) and also as compared with the 100 mg dose (p <0001 for both) to values within the secretory phase range. Premenopausal total suppression of hyperplasia in women receiving continuous oestrogen treatment,8 and we prescribed oral progesterone for only 10 days each month. In our opinion, however, the 100 mg dose is too low for use in postmenopausal women taking exogenous oestrogens. Similar comments apply to the 200 mg dose, which caused secretory transformation in 10 of 13 samples (77%). In nine of these 10 specimens, however, a mixed endometrial pattern was observed, secretory features coexisting with proliferative and non-secretory type glands. Giant mitochondria were observed in six but nucleolar channel systems were seen in only two of the 11 specimens, and the combined score was 59% (27/46 The biochemical effects of oral progesterone were similarly dose dependent. Suppression of DNA synthesis and nuclear oestradiol receptor, which provide an index of antioestrogenic effects of oral progesterone, and induction of enzymatic activity, which assesses the secretory effects, were clearly suboptimal with the 100 mg dose. Values comparable to the premenopausal secretory phase range were induced by progesterone 300 mg. Intermediate effects were observed with the 200 mg dose.
Reasons for the discrepancy between the morphological and biochemical responses to progesterone 300 mg are unclear. With the androgenic progestogens norethisterone and DLnorgestrel we have reported a close correlation between the morphological and biochemical effects.5 6 Thus, although oral progesterone undoubtedly exerts an end organ effect within the endometrium, the inability of 300 mg to induce uniform secretory and fine structural features suggests that larger doses may be required. Potential disadvantages to increasing the dose further include the development of adverse physical and psychological effects, whereas a potential advantage might be in increasing the efficiency of regular endometrial shedding. The latter is currently believed to be important in protecting against endometrial hyperplasia and is manifested by bleeding per vaginam.
Physical and psychological side effects and the patterns of bleeding per vaginam due to oral progesterone were recorded in this study and these data will be published in detail separately. In summary, the incidence of the commonest side effect, of a premenstrual tension like syndrome, was not dose dependent, being reported by 13"', of patients taking 100 mg and by 17%/o of patients taking 300 mg. Only 43',' of patients taking 100 mg experienced withdrawal bleeding after progesterone administration, and the lack of endometrial shedding on a regular monthly basis may help explain the development of endometrial hyperplasia in three patients within this group, the retained endometrium being subjected to a chronic oestrogenic stimulus. With 300 mg, 77%,' of patients experienced regular withdrawal bleeding. Thus larger doses are unlikely, in our opinion, to increase the incidence of physical or psychological side effects, or both, but may effect more efficient endometrial shedding.
We believe that because oral progesterone does not cause gross adverse metabolic effects,21 22 
